☆ 4.6 Letter

SARS-CoV-2 persistence and non-protective immunity in infected haematological patients

BRITISH JOURNAL OF HAEMATOLOGY (2021)

期刊

BRITISH JOURNAL OF HAEMATOLOGY

卷 192, 期 2, 页码 E51-E54

出版社

WILEY

DOI: 10.1111/bjh.17212

关键词

SARS-CoV-2; COVID-19; immunity; persistence

类别

Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Immunology

Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients

Yanan Wang, Jingjing Li, Huijun Li, Ping Lei, Guanxin Shen, Chunguang Yang

Summary: The study found that in COVID-19 patients, the positive rate of virus-specific IgM peaked from the second week to the eighth week after infection, but quickly declined in the twelfth week; concentrations of IgG remained high for at least 3 months before subsequently declining; serum IgM levels were significantly higher in patients with severe symptoms compared to those with mild symptoms.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Review Multidisciplinary Sciences

COVID-19 vaccination: The road ahead

Daniel M. Altmann, Rosemary J. Boyton

Summary: A diverse range of first-generation SARS-CoV-2 vaccines have been successful in controlling the COVID-19 pandemic, although inequitable distribution remains an issue. Future challenges include optimizing immunological boosting strategies and building an immune repertoire that can protect against upcoming viral variants.

SCIENCE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Untangling introductions and persistence in COVID-19 resurgence in Europe

Philippe Lemey, Nick Ruktanonchai, Samuel L. Hong, Vittoria Colizza, Chiara Poletto, Frederik Van den Broeck, Mandev S. Gill, Xiang Ji, Anthony Levasseur, Bas B. Oude Munnink, Marion Koopmans, Adam Sadilek, Shengjie Lai, Andrew J. Tatem, Guy Baele, Marc A. Suchard, Simon Dellicour

Summary: In late summer 2020, more than half of the SARS-CoV-2 lineages circulating in many European countries resulted from new introductions, and the success in onward transmission of these newly introduced lineages was negatively associated with the local incidence of COVID-19. The widespread dissemination of variants in summer 2020 highlights the threat of viral spread when restrictions are lifted.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

C. Sabrina Tan, Ai-ris Y. Collier, Jingyou Yu, Jinyan Liu, Abishek Chandrashekar, Katherine McMahan, Catherine Jacob-Dolan, Xuan He, Vicky Roy, Blake M. Hauser, Jennifer E. Munt, Michael L. Mallory, Melissa Mattocks, John M. Powers, Rita M. Meganck, Marjorie Rowe, Rachel Hemond, Esther A. Bondzie, Kate H. Jaegle, Ralph S. Baric, Aaron G. Schmidt, Galit Alter, Mathieu Le Gars, Jerald Sadoff, Dan H. Barouch

Summary: By using heterologous Ad26.COV2.S vaccine as a booster for individuals previously vaccinated with BNT162b2, durable humoral and cellular immune responses can be achieved. This suggests potential benefits of heterologous prime-boost vaccine regimens for SARS-CoV-2.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Persistence of IgG COVID-19 antibodies: A longitudinal analysis

Alvaro Carvalho, Ana Rita Henriques, Paula Queiros, Joana Rodrigues, Nuno Mendonca, Ana Maria Rodrigues, Helena Canhao, Germano de Sousa, Francisco Antunes, Miguel Guimaraes

Summary: This study aimed to evaluate the antibody responses to SARS-CoV-2 and its dynamics during 9 months in COVID-19 patients. The results showed a lasting anti-S IgG antibody response after 9 months in the majority of patients. Factors such as age and symptomatic disease were found to be associated with different concentrations of IgG antibodies. Overall, this study provides important insights into the immune response to SARS-CoV-2 and has implications for preventive strategies and public health policies.

FRONTIERS IN PUBLIC HEALTH (2023)

添加到收藏夹

Article Immunology

Age-adjusted impact of prior COVID-19 on SARS-CoV-2 mRNA vaccine response

Sachie Nakagama, Yu Nakagama, Yuko Komase, Masaharu Kudo, Takumi Imai, Evariste Tshibangu-Kabamba, Yuko Nitahara, Natsuko Kaku, Yasutoshi Kido

Summary: More people with a history of prior infection are receiving SARS-CoV-2 vaccines. Understanding the level of protection granted by 'hybrid immunity', the combined response of infection- and vaccine-induced immunity, may impact vaccination strategies through tailored dosing. Analysis of participants with prior infection showed higher antibody titers and enhanced immune response, especially among older individuals. These findings contribute to the growing body of evidence supporting the effectiveness of booster vaccinations following prior infection.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Biology

Spatial transcriptome atlas reveals pulmonary microstructure-specific COVID-19 gene signatures in cynomolgus macaques

Taehwan Oh, Green Kim, Seung Ho Baek, Youngmin Woo, Bon-Sang Koo, Eun-Ha Hwang, Kyuyoung Shim, You Jung An, Yujin Kim, Jinyoung Won, Youngjeon Lee, Kyung Seob Lim, Jae-Hak Park, Jung Joo Hong

Summary: We utilized a spatial transcriptome atlas to identify specific gene expression profiles of acute lung injury during SARS-CoV-2 infection. The alveolar regions showed activation of genes related to virus-induced cell death and the innate immune response, while inflamed vascular regions exhibited upregulation of interferon and complement pathway genes. Known biomarker genes were expressed in specific pulmonary microstructures, highlighting the importance of identifying key drivers of disease progression and clinically applicable biomarkers during SARS-CoV-2 infection.

COMMUNICATIONS BIOLOGY (2023)

添加到收藏夹

Article Engineering, Environmental

Persistence of SARS-CoV-2 RNA in wastewater after the end of the COVID-19 epidemics

Shaolin Yang, Qian Dong, Siqi Li, Zhao Cheng, Xiaofeng Kang, Daheng Ren, Chenyang Xu, Xiaohong Zhou, Peng Liang, Lingli Sun, Jianhong Zhao, Yang Jiao, Taoli Han, Yanchen Liu, Yi Qian, Yi Liu, Xia Huang, Jiuhui Qu

Summary: This study conducted a field trial on the presence of SARS-CoV-2 in wastewater facilities in Beijing after the end of the COVID-19 epidemics. The results showed that the wastewater treatment facility is a large repository for SARS-CoV-2. The viral RNA was still present in hospital sewage for 15 days and in municipal wastewater treatment plants for more than 19 days. The study highlights the persistence of SARS-CoV-2 RNA in wastewater, especially at lower temperatures.

JOURNAL OF HAZARDOUS MATERIALS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical correlates of anti-SARS-CoV-2 antibody profiles in Spanish COVID-19 patients from a high incidence region

Robert Markewitz, Antje Torge, Klaus-Peter Wandinger, Daniela Pauli, Andre Franke, Luis Bujanda, Jose Maria Marimon, Jesus M. Banales, Maria A. Gutierrez-Stampa, Beatriz Nafria, Ralf Junker

Summary: The presence and levels of anti-SARS-CoV-2 antibodies are mainly dependent on the time between symptom onset and serum collection, with some patients not developing antibodies at the time of sample collection. No significant associations were found between the presence and levels of antibodies and age, sex, duration of hospitalization, treatment in the ICU or death.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Review Medicine, General & Internal

Diagnostics for COVID-19: moving from pandemic response to control

Rosanna W. Peeling, David L. Heymann, Yik-Ying Teo, Patricia J. Garcia

Summary: Diagnostics play a crucial role in the response to the COVID-19 pandemic. Molecular tests like PCR are recommended for confirming diagnosis in symptomatic individuals, while antigen rapid detection tests have the advantage of being easier to perform with faster results and lower cost. Antibody tests can inform public policy but should not be used as proof of immunity. All three types of tests continue to be important in transitioning from pandemic response to control.

LANCET (2022)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Felicity Liew, Shubha Talwar, Andy Cross, Brian J. Willett, Sam Scott, Nicola Logan, Matthew K. Siggins, Dawid Swieboda, Jasmin K. Sidhu, Claudia Efstathiou, Shona C. Moore, Chris Davis, Noura Mohamed, Jose Nunag, Clara King, A. A. Roger Thompson, Sarah L. Rowland-Jones, Annemarie B. Docherty, James D. Chalmers, Ling-Pei Ho, Alexander Horsley, Betty Raman, Krisnah Poinasamy, Michael Marks, Onn Min Kon, Luke Howard, Daniel G. Wootton, Susanna Dunachie, Jennifer K. Quint, Rachael A. Evans, Louise V. Wain, Sara Fontanella, Thushan I. de Silva, Antonia Ho, Ewen Harrison, J. Kenneth Baillie, Malcolm G. Semple, Christopher Brightling, Ryan S. Thwaites, Lance Turtle, Peter J. M. Openshaw

Summary: This study examined the nasal and plasma antibody responses in COVID-19 hospitalized patients one year after discharge and vaccination. The findings showed sustained elevated antibody responses in both nasal and plasma samples for at least 12 months, but the nasal antibody response was minimally influenced by vaccination. These findings highlight the importance of developing vaccines that enhance nasal immunity.

EBIOMEDICINE (2023)

添加到收藏夹

Article Immunology

Quantitative Analysis of SARS-CoV-2 Serological Responses Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections

Kathryn Macrae, Catherine Yuqing Gong, Prameet Sheth, Jorge Martinez-Cajas, Yanping Gong

Summary: This study aimed to evaluate the antibody responses post three doses of COVID-19 vaccination in the Canadian population. The results showed that most vaccines were effective in producing robust antibody responses, and the more doses were given, the higher the serological response. However, a significant number of participants had lower antibody levels compared to the average levels prior to breakthrough infections, indicating the need for additional vaccination to ensure immunity against SARS-CoV-2.

VACCINES (2022)

添加到收藏夹

Article Immunology

An immunological autobiography: my year as a COVID-19 vaccine trial participant

Ross M. Kedl

Summary: This article describes the pre- and post-immunization experiences of an individual who participated in the Moderna phase III clinical trial and strongly suggests that the individual did not receive the placebo. Although the analysis is based on a single case, the results align well with existing published data and provide a comprehensive longitudinal evaluation of vaccine-elicited immunity within a single person. The findings, although anecdotal, offer valuable insights and guidance for future longitudinal studies with statistical significance.

NPJ VACCINES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Erin M. Bange, Nicholas A. Han, Paul Wileyto, Justin Y. Kim, Sigrid Gouma, James Robinson, Allison R. Greenplate, Madeline A. Hwee, Florence Porterfield, Olutosin Owoyemi, Karan Naik, Cathy Zheng, Michael Galantino, Ariel R. Weisman, Caroline A. G. Ittner, Emily M. Kugler, Amy E. Baxter, Olutwatosin Oniyide, Roseline S. Agyekum, Thomas G. Dunn, Tiffanie K. Jones, Heather M. Giannini, Madison E. Weirick, Christopher M. McAllister, N. Esther Babady, Anita Kumar, Adam J. Widman, Susan DeWolf, Sawsan R. Boutemine, Charlotte Roberts, Krista R. Budzik, Susan Tollett, Carla Wright, Tara Perloff, Lova Sun, Divij Mathew, Josephine R. Giles, Derek A. Oldridge, Jennifer E. Wu, Cecile Alanio, Sharon Adamski, Alfred L. Garfall, Laura A. Vella, Samuel J. Kerr, Justine Cohen, Randall A. Oyer, Ryan Massa, Ivan P. Maillard, Kara N. Maxwell, John P. Reilly, Peter G. Maslak, Robert H. Vonderheide, Jedd D. Wolchok, Scott E. Hensley, E. John Wherry, Nuala J. Meyer, Angela M. DeMichele, Santosha A. Vardhana, Ronac Mamtani, Alexander C. Huang

Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.

NATURE MEDICINE (2021)

添加到收藏夹

Article Immunology

Vaccines Against COVID-19: A Review

Carlos U. Torres-Estrella, Maria del Rocio Reyes-Montes, Esperanza Duarte-Escalante, Monica Sierra Martinez, Maria Guadalupe Frias-De-Leon, Gustavo Acosta-Altamirano

Summary: This paper describes the current status of COVID-19 vaccine development and production, and proposes ideas for future research. The paper also discusses the immune effects of vaccination in different populations and the role of Mexico in managing the vaccination process.

VACCINES (2022)

添加到收藏夹

Review Oncology

Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management

Thomas P. Thomopoulos, Argiris Symeonidis, Alexandra Kourakli, Sotirios G. Papageorgiou, Vasiliki Pappa

Summary: Chronic neutrophilic leukemia (CNL) is a rare disease characterized by increased white blood cell counts and varied clinical presentation. The prognosis is relatively poor and current treatment options are limited.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders

Argiris Symeonidis, Spiros Chondropoulos, Evgenia Verigou, Vasileios Lazaris, Alexandra Kourakli, Panagiotis Tsirigotis

Summary: Chronic myelomonocytic leukemia and other myelodysplastic syndromes/myeloproliferative neoplasms show clinical and prognostic heterogeneity and currently lack clear therapeutic guidelines and effective treatment options. Allogeneic stem cell transplantation is the only potentially curative treatment, but its widespread use is limited by associated risks and complications. Determining patient eligibility for transplantation is crucial.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Lionel Ades, Larisa Girshova, Vadim A. Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas Faller, Mikkael A. Sekeres

Summary: The study compared the efficacy of pevonedistat+azacitidine to azacitidine monotherapy in patients with newly diagnosed higher-risk myelodysplastic syndromes and found that in certain patient populations, the new treatment may yield better clinical outcomes, while continued therapy could potentially improve survival.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Oncology

Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA

Meral Beksac, Ivan Spicka, Roman Hajek, Sara Bringhen, Tomas Jelinek, Thomas Martin, Gabor Mikala, Philippe Moreau, Argiris Symeonidis, Andreea M. Rawlings, Helgi van de Velde, Paul G. Richardson

Summary: The studies showed that isatuximab combined with pomalidomide and dexamethasone or carfilzomib and dexamethasone improved progression-free survival in patients with relapsed and/or refractory multiple myeloma, especially in those with soft-tissue plasmacytomas. The treatment had a similar median PFS compared to patients without soft-tissue plasmacytomas who received standard therapy. Safety profiles were reported individually per study.

LEUKEMIA RESEARCH (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome

Panagiotis T. Diamantopoulos, Emmanouil Charakopoulos, Argiris Symeonidis, Ioannis Kotsianidis, Nora-Athina Viniou, Vassiliki Pappa, Charalampos Pontikoglou, Dimitrios Tsokanas, Georgios Drakos, Alexandra Kourakli, Elena Solomou, Eleftheria Hatzimichael, Anastasia Pouli, Maria Kotsopoulou, Evangelos Asmanis, Maria Dimou, Panayiotis Panayiotidis, Sotirios Papageorgiou, Georgios Vassilopoulos, Achilles Anagnostopoulos, Theodoros Vassilakopoulos, Helen Papadaki, Athanasios Galanopoulos

Summary: Monocytopenia is a common finding in patients with myelodysplastic syndrome (MDS), and its presence is associated with excess blasts and higher prognostic scoring system categories. Monocytopenia is a prognostic indicator of lower overall survival and leukemia free survival in MDS patients, even after adjusting for other factors. Monocytopenia can also help differentiate prognostically distinct subgroups in the low and intermediate risk groups of MDS.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Meeting Abstract Hematology

The Transcription Factor ETS-1 Correlates with the Increased Age Associated B Cells in Patients with Acquired Aplastic Anemia

Elena E. Solomou, Antonis Kattamis, Argiris Symeonidis, Haroula Sirinian, Christina Salamaliki, Panagiotis T. Diamantopoulos, Athanasios Galanopoulos, Maria D. Palasopoulou, Christina-Nefeli Kontandreopoulou, Nikolaos Giannakoulas, Nora-Athina Viniou, Stamatis-Nick Liossis, George Vassilopoulos

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Real-World Data on the Use of Luspatercept in Greek Patients with Transfusion Dependent Thalassemia

Polyxeni Delaporta, Alexandra Kourakli, Sophia Delicou, Michael D. Diamantidis, Chrysoula Kalkana, Efthymia Vlachaki, Eftychios Eftychiadis, Ioannis Lafiatis, Despoina Pantelidou, Argiris Symeonidis, Vasileios Lazaris, Aikaterini Xydaki, Achilles Manafas, Loukia Evliati, Filippos Klonizakis, Ioanna Manika, Despoina Papadopoulou, Marianna Chatzieleftheriou, Konstantina Toutoudaki, Dimitra Kyriakopoulou, Antonis Kattamis

BLOOD (2022)

添加到收藏夹

Article Hematology

Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry

Krzysztof Madry, Karol Lis, Pierre Fenaux, David Bowen, Argiris Symeonidis, Moshe Mittelman, Reinhard Stauder, Jaroslav Cermak, Guillermo Sanz, Eva Hellstrom-Lindberg, Saskia Langemeijer, Luca Malcovati, Ulrich Germing, Mette Skov Holm, Agnes Guerci-Bresler, Dominic Culligan, Laurence Sanhes, Ioannis Kotsianidis, Corine van Marrewijk, Simon Crouch, Theo de Witte, Alex Smith

Summary: Information on causes of death and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS is limited. This study shows that MDS and its related complications play a crucial role in the outcome of patients with lower-risk MDS.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Article Oncology

Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries

Konstantinos Liapis, Vasileios Papadopoulos, Charalambos Pontikoglou, George Vrachiolias, Emily Stavroulaki, Alexandra Kourakli, Vasileios Lazaris, Athanasios G. Galanopoulos, Menelaos Papoutselis, Sotirios G. Papageorgiou, Panagiotis T. Diamantopoulos, Vassiliki Pappa, Nora-Athina Viniou, Dimitris Tsokanas, Theodoros P. Vassilakopoulos, Eleftheria Hatzimichael, Eleni Bouronikou, Maria Ximeri, Aekaterini Megalakaki, Panagiotis Zikos, Panayiotis Panayiotidis, Maria Dimou, Stamatis Karakatsanis, Maria Papaioannou, Stavros Papadakis, Anna Vardi, Flora Kontopidou, Nikolaos Harchalakis, Ioannis Adamopoulos, Argiris Symeonidis, Helen A. Papadaki, Ioannis Kotsianidis

LEUKEMIA (2023)

添加到收藏夹

Letter Hematology

The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms

Panagiotis T. Diamantopoulos, Elena Solomou, Argiris Symeonidis, Vasiliki Pappa, Ioannis Kotsianidis, Athanasios Galanopoulos, Charalampos Pontikoglou, Achilles Anagnostopoulos, George Vassilopoulos, Panagiotis Zikos, Eleftheria Hatzimichael, Maria Papaioannou, Aekaterini Megalakaki, Theodoros Vassilakopoulos, Maria Dimou, Dimitrios Tsokanas, Menelaos-Konstantinos Papoutselis, Sotirios Papageorgiou, Alexandra Kourakli, Helen Papadaki, Panayiotis Panayiotidis, Nora-Athina Viniou

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Letter Hematology

Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study

Efstathios Kastritis, Evangelos Terpos, Argiris Symeonidis, Vasiliki Labropoulou, Sosana Delimpasi, Katia Mancuso, Elena Zamagni, Eirini Katodritou, Elena Rivolti, Marie-Christine Kyrtsonis, Maria Roussou, Despina Fotiou, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Evdoxia Hatjiharissi, Nikolaos Kanellias, Magdalini Migkou, Giorgos Cheliotis, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Letter Oncology

Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes

Ioannis Mitroulis, Vasileios Papadopoulos, Eleftheria Lamprianidou, Peter Mirtschink, Konstantinos Liapis, Kalliopi Zafeiropoulou, Alexandra Kourakli, Theodoros Moysiadis, Menelaos Papoutselis, George Vrachiolias, Argiris Symeonidis, Ioannis Kotsianidis

BLOOD CANCER JOURNAL (2023)

添加到收藏夹

Editorial Material Oncology

Hybrid or mixed myelodyplastic/myeloproliferative disorders: Current trends in diagnosis and treatment

Argiris Symeonidis, Ulrich Germing

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeted Proteomic Analysis of Patients with Ascending Thoracic Aortic Aneurysm

Aphrodite Daskalopoulou, Sotiria G. Giotaki, Konstantina Toli, Angeliki Minia, Vaia Pliaka, Leonidas G. Alexopoulos, Gerasimos Deftereos, Konstantinos Iliodromitis, Dimitrios Dimitroulis, Gerasimos Siasos, Christos Verikokos, Dimitrios Iliopoulos

Summary: This study aimed to identify potential biomarkers for ascending thoracic aneurysm (ATAA) using targeted proteomic analysis. CCL5, HBD1, and ICAM1 were found to be promising biomarkers with satisfying sensitivity and specificity, which could be helpful in the diagnosis and follow-up of ATAA patients. Further studies are warranted to investigate the role of these biomarkers in the pathogenesis of ATAA.

BIOMEDICINES (2023)

添加到收藏夹

Article Genetics & Heredity

Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response

Stavroula Siamoglou, Ruben Boers, Maria Koromina, Joachim Boers, Anna Tsironi, Theodora Chatzilygeroudi, Vasileios Lazaris, Evgenia Verigou, Alexandra Kourakli, Wilfred F. J. van IJcken, Joost Gribnau, Argiris Symeonidis, George P. Patrinos

Summary: Myelodysplastic syndromes (MDS) are a group of hematological malignancies characterized by ineffective hematopoiesis, cytogenetic abnormalities, and a high risk of transformation to acute myeloid leukemia (AML). This study used methylated DNA sequencing (MeD-seq) to identify potential epigenomic targets associated with MDS subtypes. The results identified differentially methylated CpG islands, transcription start sites, and post-transcriptional start sites within the PCDHG and ZNF gene families. These findings provide important insights into the epigenomic component of MDS pathogenesis and the potential for targeted drug treatment.

HUMAN GENOMICS (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.